glp·helper
glphelper.com/semaglutide/north-carolina/huntersville
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Huntersville, NC

Verified Semaglutide providers in Huntersville, NC. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
31
as of today
§ 02Provider directory: North Carolina
31 of 31 shown

Find a Semaglutide provider in North Carolina.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by North Carolina city · /semaglutide/north-carolina/{city}
§ 03Getting Semaglutide in Huntersville
31 providers · Huntersville, NC

How to get Semaglutide in Huntersville.

31 GLP-1 prescribers and 7 local resource types are on record for Huntersville, plus 3 nearby towns in the directory.

Prescribers in Huntersville
31 prescribers
31 GLP-1 prescribers in Huntersville, most listed as Family Medicine (12), Internal Medicine, Endocrinology, Diabetes & Metabolism (9) and Internal Medicine (8). Any North Carolina-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Cornelius (22 providers), Mooresville (22 providers) and Concord (30 providers).
Around the prescription in Huntersville
7 listed nearby
45 dietitians, 5 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Huntersville.
Medicaid (weight loss)
Covered
As of April 2026, North Carolina Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Huntersville

Huntersville, North Carolina has a population of 61,376 people. The adult obesity rate in Huntersville is an age-adjusted estimate of 25.6%, 8.9 percentage points below the North Carolina state rate of 34.5%. Diagnosed diabetes reaches 7.6% of adults in Huntersville. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 16% of adults in Huntersville.

of Huntersville adults have obesity
25.6%
diagnosed diabetes
7.6%
no regular physical activity
16%

Age-adjusted estimates for Huntersville, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossdo oral GLP-1 pills work
§ 05Support around Semaglutide in Huntersville
6 fitness clubs

The prescription is one part. Here is the rest, in Huntersville.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Huntersville, NC, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Huntersville Recreation Center
REC CENTER
4.7 on Google · 174 reviews
11836 Verhoeff Dr
Website
RockBox Fitness Huntersville
BOXING
4.6 on Google · 130 reviews
9615 Sherrill Estates Rd A
Website
Gold's Gym Huntersville
GYM
4.2 on Google · 248 reviews
13108-B Eastfield Rd
Website
Anytime Fitness
GYM
4.7 on Google · 171 reviews
9856 Gilead Rd
Website
CrossFit Huntersville
GYM
5.0 on Google · 104 reviews
9705 Rosewood Meadow Ln
Website
Activ Fitness
GYM
4.9 on Google · 88 reviews
14212 Statesville Rd Ste D
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Anjana Agarwal, MS RD LDN CNSD
RD
Registered dietitian
16501 D Northcross Drive
Call 704-895-9865NPI 1356415715
Emily Batten, MS, RD, LDN
RD
Registered dietitian
10130 Mallard Creek Rd Ste 300
Call 704-989-3262NPI 1407258791
Kaylie Booth
RD
Registered dietitian
7022 Carrington Pointe Dr
Call 256-797-6079NPI 1114784626
Megan Carber, RD, LDN
RD
Registered dietitian
14509 S Old Statesville Rd Ste 104
Call 704-966-9876NPI 1598011389
Diane Carroll, MS, RDN
RD
Registered dietitian
10133 Lafoy Dr
Call 704-948-0789NPI 1912339375
Corey Colson, RDN
RD
Registered dietitian
6060 Piedmont Row Dr S Fl 6
Call 704-489-3094NPI 1518328574
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in North Carolina

NPI-verified Semaglutide (semaglutide) prescribers and clinics, never ranked by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in North Carolina

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]